Postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer: a systematic review and practice guideline

A Multicenter Retrospective Analysis of Survival Outcome Following Postoperative Chemoradiotherapy in Non–Small-Cell Lung Cancer Patients With N2 Nodal Disease

“…The survival advantage associated with POCRT in our analysis was consistent with that in some previous reports (6). POCRT had significantly better LRFS (11,20,21,(23)(24)(25), which resulted in significantly improved DFS and OS, when POCRT was compared with POCT (26,27). As shown in Fig.…”

“…PORT is also acceptable for patients with N2 stage disease (8)(9)(10)(11)(12)(13); however, the effect of the therapeutic modality of adjuvant chemoradiotherapy remains unclear (8,20,21). Here, our study is to evaluate the addition of PORT to adjuvant chemotherapy focusing on patients with completely resected NSCLC with N2 node involvement.…”

“…Whether PORT is associated with increased death from intercurrent diseases is still a matter of debate (6,28). Some clinical results including meta-analysis trials demonstrated a detrimental effect of PORT on survival in Stage I/II disease, and a potential benefit of PORT in patients with N2 stage disease (21,(23)(24)(25)(26)(27)(28). The detrimental effect on survival was attributed to the 21% relative increase in the risk of death associated with PORT, which was administered with just one radiotherapy field each day and by a cobalt machine (6).…”

Postoperative Radiation Therapy for Patients Who Have Resected Non–Small Cell Lung Cancer

“…It is doubtful that the results for local control or toxicity would be similar for patients who were planned for and treated using modern RT techniques. wagner Okakura et al [23], writing for the Cancer Care Ontario Program in EvidenceBased Cancer Care, also published a review of prospective trials of PORT in NSCLC. They conducted a formal review of all published literature (full publications and abstracts) and included three newer trials and updated data which had not been included in the initial PORT meta-analysis.…”

Is postoperative chemotherapy and/or postoperative radiotherapy in stage IIIA non-small cell lung cancer feasible?

“…Two articles have been published in Lung Cancer, one by Okawara et al [1] about postoperative radiotherapy in stage II or IIIA completely resected non-small cell lung cancer, and the second by Alam et al [2] about compliance with postoperative adjuvant chemotherapy in non-small cell lung cancer.…”